{"id":2357,"date":"2021-06-15T09:40:07","date_gmt":"2021-06-15T08:40:07","guid":{"rendered":"https:\/\/touchimmunology.com\/?post_type=media_gallery&#038;p=2357"},"modified":"2023-03-07T12:00:57","modified_gmt":"2023-03-07T12:00:57","slug":"siew-eng-choon-aad-vmx-2021-spesolimab-in-generalised-pustular-psoriasis","status":"publish","type":"media_gallery","link":"https:\/\/touchimmunology.com\/psoriasis\/conference-hub\/siew-eng-choon-aad-vmx-2021-spesolimab-in-generalised-pustular-psoriasis\/","title":{"rendered":"Siew Eng Choon, Dermatology Meeting News 2021: Spesolimab in Generalised Pustular Psoriasis"},"content":{"rendered":"<p>It was a pleasure to speak with <strong>Dr Siew Eng Choon<\/strong> (Monash University, Malaysia) about the first RCT trial conducted in generalised pustular psoriasis (GPP). Effisayil 1 (NCT03782792) is a Phase 2 trial investigating the anti-IL-36 receptor antibody, spesolimab.<\/p>\n<p>The abstract entitled \u2018<em>Design and rationale of Effisayil 1, a Phase II, multicenter, randomized, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis with an acute flare<\/em>\u2019 was presented at AAD VMX, 23-25 April, 2021.<\/p>\n<p><em>This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.\u00a0<\/em><\/p>\n<p><strong>Questions<\/strong><\/p>\n<ol>\n<li>What is the rationale for the use of spesolimab in the treatment of patients with a GPP flare? (0:21)<\/li>\n<li>What are the challenges of testing the efficacy and safety of new therapies in GPP? (2:09)<\/li>\n<li>How does the design and clinical endpoints of the Effisayil 1 study aim to overcome these challenges? (4:52)<\/li>\n<\/ol>\n<p><strong>Disclosures:<\/strong> Dr Siew Eng Choon has received honoraria for serving as a consultant, advisory board member, and\/or speaker for AbbVie, Boehringer Ingelheim, Janssen, Leo, Eli Lilly, Leo, Novartis, Pfizer, GlaxoSmithKline, UCB, MSD and Wyeth.<\/p>\n<p><strong>Support:<\/strong> Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.<\/p>\n<p><em><strong>Filmed in coverage of the AAD VMX 2021.<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>It was a pleasure to speak with Dr Siew Eng Choon (Monash University, Malaysia) about the first RCT trial conducted in generalised pustular psoriasis (GPP). Effisayil 1 (NCT03782792) is a Phase 2 trial investigating the anti-IL-36 receptor antibody, spesolimab. The abstract entitled \u2018Design and rationale of Effisayil 1, a Phase II, multicenter, randomized, double-blind, placebo-controlled [&hellip;]<\/p>\n","protected":false},"featured_media":2355,"template":"","class_list":["post-2357","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-psoriasis"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/2357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":5,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/2357\/revisions"}],"predecessor-version":[{"id":11512,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/2357\/revisions\/11512"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media\/2355"}],"wp:attachment":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media?parent=2357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}